Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Bethesda North Marriott Hotel and Conference Center

Apr 25, 2022 7:00 AM - Apr 27, 2022 12:00 PM

5701 Marinelli Road, , North Bethesda, MD 20852 , USA

DIA/FDA Oligonucleotide-Based Therapeutics Conference

DIA Your Way! Join us live in-person or live from the comfort of your home/office. This event offers two learning avenues depending on your preference!

Session 5 Track 3: ICH Q14 Regulatory Perspective and the Impact on Process Analytical Technology

Session Chair(s)

Claus  Rentel, PhD

Claus Rentel, PhD

Vice President, Analytical Development and Quality Control

Ionis Pharmaceuticals, Inc., United States

A new quality guideline, ICHQ14, on analytical procedure development is being developed. The intent of this guideline is to harmonize scientific approaches of analytical procedure development in both traditional and enhanced approaches. Thus, resulting in improved regulatory communication between industry and regulators by facilitating efficient and science-based change management. The session will include presentations from a member of the working group as well as industry experience implementing PAT for an oligonucleotide therapeutic. The presentations will be followed by a panel discussion.

Learning Objective :
  • Understand concepts of an enhanced approach to analytical method development and Quality by Design (QbD) principles like Risk Assessment, Design Space, and Control Strategy
  • Introduce ICH Q14 principles to analytical method validation
  • Learn about applications of PAT and the use of multivariate models in oligonucleotide manufacturing
  • Understand regulatory acceptance of strategies differing from traditional analytical method validations


Daniel  Hill, MBA


Daniel Hill, MBA

Biogen, United States

Associate Director Digital Development and Analytics

Nina S. Cauchon, PhD


Nina S. Cauchon, PhD

Amgen, United States

Director Regulatory Affairs CMC

Bryan  Castle, PhD


Bryan Castle, PhD

Eli Lilly and Company, United States

Executive Director, Synthetic Molecule Design & Development

Bogdan  Kurtyka, PhD


Bogdan Kurtyka, PhD

FDA, United States

Senior Process Quality Assessor

René  Thürmer, PhD


René Thürmer, PhD

Federal Institute for Drugs and Medical Devices, Germany

Deputy Head of the Unit Pharmaceutical Biotechnology BfArM

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.